BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models
Open accessThe DOI matches its Crossref record; 41 of the 45 references it cites were found in a registry or an index.
Abstract
Background: The tumor suppressor TP53 (p53) is frequently mutated, and its downstream effectors inactivated in many cancers, including glioblastoma (GBM). In tumors with wild-type status, p53 function is frequently attenuated by alternate mechanisms including amplification and overexpression of its key negative regulator, MDM2. We investigated the efficacy of the MDM2 inhibitor, BI-907828, in GBM patient-derived brain tumor stem cells (BTSCs) with different amplification statuses of MDM2, in vitro and in orthotopic xenograft models. Methods: In vitro growth inhibition and on-target efficacy of BI-907828 were assessed by cell viability, co-immunoprecipitation assays, and western blotting. In vivo efficacy of BI-907828 treatments was assessed with qPCR, immunohistochemistry, and in intracranial xenograft models. Results: BI-907828 decreases viability and induces cell death at picomolar concentrations in both MDM2 amplified and normal copy number TP53 wild-type BTSC lines. Restoration of p53 activity, including robust p21 expression and apoptosis induction, was observed in TP53 wild-type but not in TP53 mutant BTSCs. shRNA-mediated knock-down of TP53 in wild-type BTSCs abrogated the effect of BI-907828, confirming the specificity of the inhibitor. Pharmacokinetic-pharmacodynamic studies in orthotopic tumor-bearing severe combined immunodeficiency (SCID) mice demonstrated that a single 50 mg/kg p.o. dose of BI-907828 resulted in strong activation of p53 target genes p21 and MIC1. Long-term weekly or bi-weekly treatment with BI-907828 in orthotopic BTSC xenograft models was well-tolerated and improved survival both as a single-agent and in combination with temozolomide, with dose-dependent efficacy observed in the MDM2 amplified model. Conclusions: BI-907828 provides a promising new therapeutic option for patients with TP53 wild-type primary brain tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite significant efflux liability, brigimadlin has promising efficacy in orthotopic GBM PDXs, especially in tumors harboring MDM2 amplification.15,27”
From Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts (2026) · cites this paper as [27]
In the citing paper
“Similar results were observed in our prior study of navtemadlin in a panel of 17 GBM PDXs; navtemadlin was profoundly more effective in MDM2-amplified vs non-amplified tumors.27”
From Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts (2026) · cites this paper as [27]
In the citing paper
“Compared to other MDM2 inhibitors, its pharmacokinetic properties allow for dose optimization, potentially reducing myelosuppressive side effects.407,408”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [408]
In the citing paper
“When taken orally, it binds to the MDM2 protein, preventing the binding of the p53 transcription-activated region, thus restoring p53 transcriptional activity which mediates tumor cell apoptosis.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [408]
In the citing paper
“BI-907828 (151) is an orally effective MDM2 inhibitor developed by BI with potential antitumor activity.”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [408]
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
Genetic Pathways to Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070011 · Cited by 1,497
p53 ubiquitination: Mdm2 and beyond
Brooks, C. L., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.020 · Cited by 924
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
Ostermann, S., Csajka, C., Buclin, T., Leyvraz, S., Lejeune, F., Decosterd, L. A., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0807 · Cited by 518
MDM2 inhibition: an important step forward in cancer therapy
Konopleva, M., Martinelli, G., Daver, N., Papayannidis, C., Wei, A., Higgins, B., Ott, M., Mascarenhas, J., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376
Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 256
MacLeod, G., Bozek, D. A., Rajakulendran, N., Monteiro, V., Ahmadi, M., Steinhart, Z., Kushida, M. M., Yu, H., Coutinho, F. J., Cavalli, F. M. G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.047 · Cited by 239
Self-citationAn in vivo patient-derived model of endogenous IDH1-mutant glioma
Luchman, H. A., Stechishin, O. D., Dang, N. H., Blough, M. D., Chesnelong, C., Kelly, J. J., Nguyen, S. A., Chan, J. A., Weljie, A. M., Cairncross, J. G., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nor207 · Cited by 198
Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous Mitogens
Kelly, J. J. P., Stechishin, O., Chojnacki, A., Lun, X., Sun, B., Senger, D. L., Forsyth, P., Auer, R. N., Dunn, J. F., Cairncross, J. G., et al. (2009) · Stem Cells · doi:10.1002/stem.98 · Cited by 187
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
Jones, S. J., Laskin, J., Li, Y. Y., Griffith, O. L., An, J., Bilenky, M., Butterfield, Y. S., Cezard, T., Chuah, E., Corbett, R., et al. (2010) · Genome Biology · doi:10.1186/gb-2010-11-8-r82 · Cited by 175
Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer
Rew, Y., & Sun, D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500627s · Cited by 125
Reis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., Dickinson, M. J., Drummond, M., Assouline, S., Hashemyan, M., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139717 · Cited by 91
Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics
Zhao, Y., Bernard, D., & Wang, S. (2013) · BioDiscovery · doi:10.7750/biodiscovery.2013.8.4 · Cited by 90
Jeay, S., Ferretti, S., Holzer, P., Fuchs, J., Chapeau, E. A., Wartmann, M., Sterker, D., Romanet, V., Murakami, M., Kerr, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0338 · Cited by 87
Shen, Y., Grisdale, C. J., Islam, S. A., Bose, P., Lever, J., Stutheit-Zhao, E. Y., Grinshtein, N., Ma, Y. P., Mungall, A. J. J., Moore, R. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1813495116 · Cited by 74
Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
Skalniak, L., Kocik, J., Polak, J., Skalniak, A., Rak, M., Wolnicka-Glubisz, A., & Holak, T. (2018) · Cancers · doi:10.3390/cancers10110396 · Cited by 73
Jensen, K. V., Cseh, O., Aman, A. M., Weiss, S., & Luchman, H. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189670 · Cited by 71
Self-citationCusulin, C., Chesnelong, C., Bose, P., Bilenky, M., Kopciuk, K. A., Chan, J. A.-W., Cairncross, J. G., Jones, S. J. M., Marra, M. A., Luchman, H. A., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.05.010 · Cited by 64
Luchman, H. A., Stechishin, O. D. M., Nguyen, S. A., Lun, X. Q., Cairncross, J. G., & Weiss, S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3389 · Cited by 62
The p53/MDM2/MDMX-targeted therapies – a clinical synopsis
Jiang, L., & Zawacka-Pankau, J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2445-9 · Cited by 62
Cornillie, J., Wozniak, A., Li, H., Gebreyohannes, Y. K., Wellens, J., Hompes, D., Debiec-Rychter, M., Sciot, R., & Schöffski, P. (2020) · Clinical and Translational Oncology · doi:10.1007/s12094-019-02158-z · Cited by 56
Gounder, M. M., Bauer, T. M., Schwartz, G. K., LoRusso, P., Kumar, P., Kato, K., Tao, B., Hong, Y., Patel, P., & Hong, D. (2020) · European Journal of Cancer · doi:10.1016/s0959-8049(20)31080-7 · Cited by 19
Hyman, D. M., Chatterjee, M., Langenberg, M. H. G., Lin, C. C., Suárez, C., Tai, D., Cassier, P. A., YAMAMOTO, N., de Weger, V. A., Jeay, S., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)32982-3 · Cited by 15
Rinnenthal, J., Rudolph, D., Blake, S., Gollner, A., Wernitznig, A., Weyer-Czernilofsky, U., Haslinger, C., Garin-Chesa, P., Moll, J., Kraut, N., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-4865 · Cited by 12
Self-citationRudolph, D., Reschke, M., Blake, S. M., Rinnenthal, J., Wernitznig, A., Weyer-Czernilofsky, U., Gollner, A., Haslinger, C., Garin‐Chesa, P., Quant, J., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-4866 · Cited by 11
Self-citationRudolph, D., Gollner, A., Blake, S., Rinnenthal, J., Wernitznig, A., Weyer-Czernilofsky, U., Haslinger, C., Garin-Chesa, P., Quant, J., McConnell, D. B., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-4868 · Cited by 7
Self-citationRudolph, D., Weyer-Czernilofsky, U., Reschke, M., Sykora, M. M., Rinnenthal, J., Blake, S. M., Gremel, G., Wernitznig, A., Gollner, A., Kraut, N., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-3197 · Cited by 3
Self-citationLuchman, H. A., Bozek, D., Hao, X., Rudolph, D., Blake, S. M., Rinnenthal, J., & Weiss, S. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-3084 · Cited by 1
Self-citation
Cited by
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wang, W., Albadari, N. G., Du, Y., Fowler, J. F., Sang, H. T., Xian, W., McKeon, F., Li, W., Zhou, J., & Zhang, R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001026 · Cited by 172
Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018–2022)
Ali, S., & Zhou, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115476 · Cited by 135
Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells
Trejo‐Solís, C., Castillo‐Rodríguez, R. A., Serrano-García, N., Silva‐Adaya, D., Vargas-Cruz, S., Chávez-Cortéz, E. G., Gallardo‐Pérez, J. C., Zavala-Vega, S., Cruz-Salgado, A., & Magaña-Maldonado, R. (2024) · Metabolites · doi:10.3390/metabo14050249 · Cited by 42
“The authors suggested that B1-907828 can cross the BBB [328].”
BackgroundHighlights on Fluorine-containing Drugs Approved by U.S. FDA in 2023
Ali, S., Bolinger, A. A., & Zhou, J. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266300245240223070242 · Cited by 32
Metadata
- Authors
- Hao, X., Bahia, R. K., Cseh, O., Bozek, D. A., Blake, S., Rinnenthal, J., Weyer-Czernilofsky, U., Rudolph, D., & Artee Luchman, H.
- Affiliations
- University of Calgary (CA)
- Boehringer Ingelheim (Austria) (AT)
- Boehringer Ingelheim RCV GmbH & Co KG , Vienna , Austria
- Arnie Charbonneau Cancer Institute, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary , Calgary, Alberta , Canada
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-12-15
- Volume
- 25
- Issue
- 5
- Pages
- 913-926
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- PMC
- PMC10158121
- OpenAlex
- W4311662637
- Cited by
- 34
- References
- 45
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 10 · 2023: 10 · 2022: 1
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuro-Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- BI 907828, MDM2 inhibitors, glioblastoma, brain tumor stem cells, wild-type p53, p53 activation, MDM2 amplification, p21, MIC-1, temozolomide combination therapy, orthotopic xenograft, pharmacokinetics, apoptosis
- MeSH terms
- Animals, Antineoplastic Agents, Brain, Glioblastoma, Heterocyclic Compounds, 4 or More Rings, Humans, Spiro Compounds, Neoplastic Stem Cells, Tumor Suppressor Protein p53, Apoptosis, Brain Stem Neoplasms, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2, Heterografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.